e-ISSN: Pending
Negative / Null Result ReportOpen accessNeoplasms. Tumors. Oncology. Including cancer and carcinogens

HER2-low and tumor infiltrating lymphocytes in triple-negative breast cancer: Are they connected?

Ximena Baez-Navarro; Nadine S. van den Ende; Anh H. Nguyen; Renata Sinke; Pieter Westenend; Johannes Bastiaan van Brakel; Claudia Stobbe; Johan Westerga · 2024 · Breast Cancer Research

WASTE classifies this as Negative / Null Result Report · AI classification, approximate

The study found no significant effect — useful as a negative control or null benchmark for your own design.

Abstract

Abstract Most patients with triple-negative breast cancer (TNBC) are not candidates for targeted therapy, leaving chemotherapy as the primary treatment option. Recently, immunotherapy has demonstrated promising results in TNBC, due to its immunogenicity. In addition, a novel antibody–drug conjugate, namely, trastuzumab-deruxtecan, has shown effectiveness in TNBC patients with low-HER2 expression (HER2-low). These novel treatment options raise the question about the potential association between the density of stromal tumor-infiltrating lymphocytes (sTILs) and the level of HER2 expression. We a

Abstract by Ximena Baez-Navarro; Nadine S. van den Ende; Anh H. Nguyen; Renata Sinke; Pieter Westenend; Johannes Bastiaan van Brakel; Claudia Stobbe; Johan Westerga, Breast Cancer Research (2024) — licensed CC BY 4.0.

About to run something similar?

Run an AI Precheck on your own design to catch failure modes like this one before you spend the time. Your first desk check is free.

WASTE indexes this work — it does not host or republish it. Failure-type classification is automated and approximate.

Metadata source: DOAJ · DOI 10.1186/s13058-024-01783-z